Safety and Efficacy of Recaticimab in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [0.03%]
瑞卡西单抗治疗脂代谢紊乱安全性和有效性的系统评价和meta分析
Mohammed R Abdeldayem,Ahmed Elsherbeeny
Mohammed R Abdeldayem
Dyslipidemia is an established risk factor for atherosclerotic cardiovascular disease (ASCVD). Recaticimab is a novel humanized monoclonal antibody that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9). It has show...
The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study [0.03%]
氯沙坦预防乳腺癌患者紫杉醇外周神经病变的疗效研究：一项随机对照研究
Aalaa Mahmoud Ahmed Shawqi Mahmoud,Emad Shash,Hayam Ateyya et al.
Aalaa Mahmoud Ahmed Shawqi Mahmoud et al.
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a condition that persists chronically in more than 60% of affected individuals, and currently there are no proven PIPN prophylaxis. Pre-clinical data suggest ...
Randomized Controlled Trial
Pharmacotherapy. 2026 Apr;46(4):e70124. DOI:10.1002/phar.70124 2026
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients [0.03%]
胰高血糖素样肽-1受体激动剂对肾移植患者蛋白尿的影响
Stephanie Shabanowitz,Ryan Clark,Rachel Bassett Allen et al.
Stephanie Shabanowitz et al.
Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown significant cardiorenal benefits in chronic kidney disea...
Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations [0.03%]
母体和儿科精准治疗知识门户(MPRINT-KP): 母体和儿科人群药理学研究现状分析
Xiaofu Liu,Aditi Shendre,Lei Wang et al.
Xiaofu Liu et al.
Pregnant women and children have been underrepresented in clinical studies due to ethical concerns and perceived vulnerabilities. This resulted in a significant gap in knowledge regarding the safety and efficacy of medications for these pop...
Aspirin Deprescribing Interventions for Primary Prevention: A Systematic Review and Proposed Guidance for Deprescribing [0.03%]
初级预防阿司匹林去处方干预措施的系统评价及去处方建议的制定
Alison Lobkovich,Hannah Ferrari,Amber Lanae Martirosov et al.
Alison Lobkovich et al.
Recent literature indicates that the benefits of aspirin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) may be equivocal to the risk. This has resulted in several organizations making updates to their clinical ...
Probiotic Supplementation as an Adjuvant Therapy in Pediatric Drug-Resistant Epilepsy: A Double-Blind Placebo-Controlled Trial [0.03%]
益生菌作为儿童药物抵抗性癫痫辅助治疗的临床双盲安慰剂对照试验
Amira R Rashdan,Sahar M El-Haggar,Ahmed Mustafa Kishk et al.
Amira R Rashdan et al.
Background: Drug-resistant epilepsy (DRE) is increasingly linked to neuroinflammatory mechanisms driven by gut dysbiosis. These mechanisms compromise blood-brain barrier integrity, enhance seizure susceptibility, and modu...
Randomized Controlled Trial
Pharmacotherapy. 2026 Mar;46(3):e70117. DOI:10.1002/phar.70117 2026
Jennifer N Clements,Julia Mesawich,Cassandra Twisdale
Jennifer N Clements
Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin le...
Oral β-Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point-Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones [0.03%]
用于复杂性尿路感染的口服β-内酰胺类药物：系统评价和与甲氧苄氨嘧啶/磺胺甲噁唑及氟喹诺酮类药物对比分析
Ashlan J Kunz Coyne,Jeannette Bouchard,Spencer H Durham et al.
Ashlan J Kunz Coyne et al.
Background: Rising resistance and toxicity concerns with fluoroquinolones (FQs) and trimethoprim/sulfamethoxazole (TMP/SMX) have prompted interest in oral β-lactams as alternatives for complicated urinary tract infection...
Comparative Study
Pharmacotherapy. 2026 Mar;46(3):e70118. DOI:10.1002/phar.70118 2026
Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients [0.03%]
一项队列研究：CYP3A5基因型对心脏移植受者的他克莫司给药需求和谷浓度的影响
Yanting Wu,Michael T Eadon,Laurie Schenkelberg et al.
Yanting Wu et al.
Background: Tacrolimus is primarily metabolized by Cytochrome P450 (CYP)3A4/5. The Clinical Pharmacogenetics Implementation Consortium recommends increasing the initial dose 1.5- to 2-fold in CYP3A5 expressers to enhance ...